Skip to main content

Michelle Dawson posts

Post published on Twitter/X on 13 Apr 2014 03:41

Twitter/X Clinical trial clinicaltrials.gov Extract quoted in the post Question asked by Dawson in the post External link integrated into the post Autism terms

Structured cited links

1 cited resource

Clinical trial Fetched Post clinicaltrials.gov

University of Colorado, Denver (2015). Phase I Nicotinic Agonist Treatment Trial for Autism. ClinicalTrials.gov. University of Colorado, Denver.

Publication date
2015
Identifier
NCT02111551
Authors
University of Colorado, Denver
Source
ClinicalTrials.gov
Reference type
clinical_trial
Publisher
University of Colorado, Denver
Metadata source
clinicaltrials.gov

Abstract

This study plans to learn more about whether a nicotine-like investigational new drug, DMXB-A \[3-(2,4-dimethoxybenzylidene) anabaseine\] may have positive effects on mental focus and may help us to find new types of treatment for autism spectrum disorder. Subjects will come in for a screening visit and three more drug visits. There will be at least one week between each drug visit to allow the drug to be eliminated from your system completely. During each drug visit subjects will receive either a placebo (a capsule that looks like medicine but is not real), 75 mg of DMXB-A, or 150 mg of DMXB-A. During the drug day vital signs and well being will be monitored by the study physician. Subjects will complete some paper and pencil tasks to test memory, attention, speed, and problem solving, some rating scales and questionnaires, and the study team will record brain wave patterns with an electroencephalogram (EEG).